SCHEMBL1563344

SCHEMBL1563344

OCc1cncc(Cl)c1COC1CCCCO1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
ICAM1 P05362 1/20 0.37
SELE P16581 1/20 0.37
KDM4C Q9H3R0 1/20 0.36
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
P2RX3 P56373 1/20 0.34
P2RX7 Q99572 5/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
CCNA2 P20248 1/20 0.32
CDK2 P24941 1/20 0.32
CCNA1 P78396 1/20 0.32
CDK5 Q00535 1/20 0.32
CDK5R1 Q15078 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1563782 0.88 PDE4D (0.41) PDE4APDE4BPDE4CPDE4DICAM1
SCHEMBL1564674 0.88 PDE4D (0.41) PDE4APDE4BPDE4CPDE4DICAM1
SCHEMBL1564757 0.88 PDE4A (0.37) PDE4APDE4BPDE4CPDE4DICAM1
SCHEMBL1564135 0.85 PDE4A (0.40) PDE4APDE4BPDE4CPDE4DICAM1
SCHEMBL2877363 0.85 ICAM1 (0.42) PDE4APDE4BPDE4CPDE4DICAM1
SCHEMBL1564706 0.85 PDE4D (0.38) PDE4APDE4BPDE4CPDE4DICAM1
SCHEMBL1564762 0.82 PDE4A (0.38) PDE4APDE4BPDE4CPDE4DICAM1
SCHEMBL2877362 0.82 PDE4A (0.34) PDE4APDE4BPDE4CPDE4DICAM1
SCHEMBL1564425 0.81 BDKRB2 (0.40) PDE4APDE4BPDE4CPDE4DICAM1
SCHEMBL1563843 0.81 BDKRB2 (0.41) PDE4APDE4BPDE4CPDE4DICAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410134-B2 8-oxy-quinoline derivatives as bradykinin B2 receptor modulators SHIRE ORPHAN THERAPIES GMBH (DE) 2013-04-02 US disclosed
EP-2305668-A1 8-oxy-quinoline derivatives as bradykinin B2 receptor modulators Jerini AG (DE) 2011-04-06 EP disclosed
EP-2144897-B1 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS JERINI AG (DE) 2010-10-20 EP disclosed
US-20100234344-A1 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS JERINI AG (DE) 2010-09-16 US disclosed
EP-2144897-A1 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS Jerini AG (DE) 2010-01-20 EP disclosed
WO-2008116620-A1 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS JERINI AG (DE) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234344-A1 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS BDKRB2, BDKRB1, HRH2 PDE4A 1209/4885PDE4B 1346/4885PDE4C 1616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.